| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-10-28 | CEVEC Pharmaceuticals (Germany) Biolamina (Sweden) | research grade and clinical grade laminins for ex vivo cell culture applications | collaboration production manufacturing |
Technology - Services | Collaboration agreement | |
| 2015-10-28 | C4X Discovery (UK) University of Oxford’s Structural Genomics Consortium department (UK) | structural, biological and therapeutic information in relation to various therapeutic targets and related assays | collaboration |
Technology - Services | Collaboration agreement | |
| 2015-10-28 | ProBioGen (Germany) Bio Farma Indonesia (Indonesia) | trastuzumab (biosimilar product) | development |
Cancer - Oncology | Development agreement | |
| 2015-10-28 | Cytoo (France) Daiichi Sankyo (Japan) | MyoScreen™ | licensing |
Neuromuscular diseases | Licensing agreement | |
| 2015-10-28 | Ipsen (France) Telesta Therapeutics (Canada) | MCNA (Mycobacterium phlei Cell wall-Nucleic Acid complex) | high risk non-muscle invasive bladder cancer (NMIBC) | licensing development commercialisation |
Cancer - Oncology | Licensing agreement |
| 2015-10-28 | Kite Pharma (USA - CA) Alpine Immune Sciences (USA - WA) | transmembrane immunomodulatory protein (TIP™) technology | R&D licensing |
Cancer - Oncology | R&D agreement | |
| 2015-10-27 | Baxalta (USA - IL) Merrimack Pharmaceuticals (USA - MA) | MM-398 | metastatic pancreatic cancer | development licensing commercialisation |
Cancer - Oncology | Milestone |
| 2015-10-27 | Ares Allergy Holdings (UK) now Stallergenes Greer (UK) | name change |
Allergic diseases | Establishment of a new subsidiary in the EU | ||
| 2015-10-27 | GW Pharmaceuticals (UK) Government of New South Wales (Australia) | Epidiolex® (cannabidiol (2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) and GWP42006 (cannabidivarin) | children with epilepsy | clinical research |
CNS diseases | Clinical research agreement |
| 2015-10-27 | Arena Pharmaceuticals (USA - CA) | restructuring |
Restructuring | |||
| 2015-10-27 | iDD Biotech (France) | nomination |
Nomination | |||
| 2015-10-27 | Allergan (Ireland) Almirall (Spain) | Constella® (linaclotide) | Irritable Bowel Syndrome with Constipation (IBS-C) | product acquisition | Digestive diseases - Gastrointestinal diseases - Inflammatory diseases | Product acquisition |
| 2015-10-26 | Ipsen (France) EpiVax (USA - RI) | next generation botulinum neurotoxin (BoNT) and Targeted Secretion Inhibitor (TSI) therapeutics | collaboration R&D development |
undisclosed | Development agreement | |
| 2015-10-26 | Corvus Pharmaceuticals (USA - CA) Genentech, a member of Roche Group (USA - CA - Switzerland) | CPI-444 and atezolizumab (MPDL3280A) | solid tumors | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-10-23 | Neurovive Pharmaceutical (Sweden) | nomination |
Nomination | |||
| 2015-10-22 | AstraZeneca (UK) Eli Lilly (USA - IN) | MEDI4736 (durvalumab), Cyramza® (ramucirumab), galunisertib, CXCR4 peptide antagonist, anti-CSF-1R monoclonal antibody, tremelimumab, abemaciclib, necitumumab, AZD9291 | advanced solid tumors | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2015-10-22 | Grifols (Spain) | Bioscience Division global operations center in Ireland | opening of new premises | Rare diseases - Genetic diseases - Hematological diseases - Immunological diseases | Opening of new premises | |
| 2015-10-21 | DBV Technologies (France) | nomination |
Allergic diseases | Nomination | ||
| 2015-10-21 | Novartis (Switzerland) Palobiofarma (Spain) | PBF-509 | licensing development |
Cancer - Oncology | Licensing agreement | |
| 2015-10-21 | Atara Biotherapeutics (USA - CA) QIMR Berghofer Medical Research Institute (Australia) | allogeneic, or "off-the-shelf", cytotoxic T-lymphocytes (CTLs) directed against multiple epitopes of the Epstein-Barr virus (EBVpoly) and multiple epitopes of the cytomegalovirus (CMVpoly) | gastric cancer, nasopharyngeal carcinoma, glioblastoma multiforme, multiple sclerosis | R&D licensing |
Autoimmune diseases - Cancer - Oncology | Licensing agreement |
